Who We Serve

Hospital-based oncology programs are increasingly evaluating whether cell therapy should become part of their service line strategy. For many, the challenge is not interest or intent. It is determining whether the organization has the capabilities, infrastructure, staffing, workflows, and financial model required to launch safely and at sufficient scale.

acCELLapy helps hospital oncology programs assess readiness, understand the market opportunity, define program requirements, and build an implementation roadmap that connects strategy to real-world clinical operations. We work with clients to create a practical path from planning to go-live, with patient safety, quality, and financial sustainability at the center.

Independent medical oncology practices often see the strategic importance of cell therapy but face a different set of constraints than hospital systems. Decisions around staffing, capital, infrastructure, reimbursement, and risk carry immediate operational and financial implications for a practice.

acCELLapy helps independent practices evaluate whether a program can be viable, what level of investment is required, and how care pathways, quality expectations, and payor dynamics must be managed to build a sustainable model. Our goal is to help practices make informed decisions and, when appropriate, build programs that are clinically sound and operationally feasible.

Multi-site oncology organizations often begin with important advantages, including shared infrastructure, centralized support functions, internal project management, and common documentation. But translating that foundation into a safe, scalable cell therapy model across practices or regions requires specialized clinical, operational, and payor expertise that can account for variation across sites and care settings.

acCELLapy helps network and MSO organizations move from foundational alignment to real implementation. We support the design of repeatable program models, readiness assessments across sites, practical operating workflows, and the capabilities required to stand up and scale cell therapy services with consistency and confidence.

For academic medical centers and existing authorized treatment centers, the challenge is often less about initial launch and more about scaling effectively. As patient demand grows, leading centers are looking for ways to increase throughput, improve economics, optimize operations, and extend appropriate aspects of care into affiliated hospitals or community settings without compromising safety or quality.

acCELLapy helps established centers evaluate where capacity constraints exist, how capabilities can be extended across a broader network, and what operational model is required to support safe decentralization of selected activities. This includes helping organizations create more access points while preserving clinical oversight, patient safety, and program integrity.

For biopharma organizations, expanding access requires more than identifying interested sites. It requires understanding which providers are most likely to succeed, what capability gaps may limit adoption, and what education, training, and enablement support can help sites become ready for current and future therapies.

acCELLapy works with biotech and pharma organizations to support market access expansion, site identification, site readiness evaluation, capability gap assessment, and provider education. Through our network of relationships and practical understanding of provider-side operations, we help biopharma organizations engage sites more effectively and support adoption in ways that are grounded in real implementation needs.